Talk:Opicinumab

Most of Commercialization section does not belong in this article

Most the Commercialization section is about Biogen and may not even be suitable for that article. I plan to move most of the section to talk:Biogen so others can decide. - Rod57 (talk) 18:10, 2 November 2018 (UTC)

Done - see Talk:Biogen#Content_removed_from_Opicinumab - Rod57 (talk) 19:50, 2 November 2018 (UTC)

Inquiry from a Public Relations Representative for Biogen on Assessing Wikipedia Article

Hello all,

My name is Matt Nemet and I am a Public Relations professional at GCI Health, an agency specializing in healthcare. We’re reaching out on behalf of our clients at Biogen to potentially update outdated information found on the Wikipedia page for its multiple sclerosis treatment candidate, opicinumab; furthermore, we were referred to reach out to this talk page directly via our recent outreach to fellow Wikipedia editor Rod57.

We are aware that per Wikipedia’s guidelines neither the company nor the company’s representatives can make direct edits to Wikipedia pages; instead, we are reaching out to qualified editors to ensure that the site has the most up-to-date information. Therefore, we would like to provide the following peer-reviewed articles for your consideration: The Lancet Neurology and CNS Drugs.

Additionally, a Phase 2 clinical trial AFFINITY was initiated to further investigate opicinumab last year, with results expected in 2020: ClinicalTrials.gov and Biogen Press Release.

Please let me know if you have any follow-up questions. Best regards, MSN2017 (talk) 21:50, 14 December 2018 (UTC)